ClinicalTrials.gg
RecruitingNCT06992427HOPEUpdated Nov 4, 2026

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

A Phase 3 interventional study of Gabapentin and Placebo in Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 and Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 216 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 4, 2026Site recruiting status changed21 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
113th of 994
228 · median 41
Started
2025
with 60 others
Phase 3
71 of 1,099
12 open now
Primary completion
2029-08
later than 297 of 346 live
Registered
1,019th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 113th largest by planned enrollment of the 994 interventional ones that give a count, is one of 61 that started in 2025, is one of 71 in phase 3, reaches primary completion later than 297 of the 346 other live ones, and was the 1,019th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation treatment and can cause severe pain, dysphagia, and weight loss resulting in feeding tube placement, worse health-related quality of life, treatment interruptions, unplanned hospitalizations, and significant financial burden. Mucositis pain is often treated with opioid pain medications which do provide pain relief but have many known side effects not limited to mental clouding, constipation, fatigue, endocrinopathy, neurotoxicity, sleep-disordered breathing, and most distressingly persistent opioid use. Gabapentin may help relieve pain from oral mucositis caused by radiation while also reducing the need for opiate pain medications for patients receiving chemotherapy and radiation for squamous cell carcinoma of the head and neck region

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine whether prophylactic high dose gabapentin, titrated to a dose of 3600 mg (1200 mg three times per day [TID]), is superior to placebo in increasing the proportion of patients not needing opiates while undergoing chemoradiation therapy.

SECONDARY OBJECTIVES:

I. To determine whether prophylactic high dose gabapentin is superior to placebo in prolonging the time to first opioid use while undergoing chemoradiation therapy.

II. To determine whether prophylactic high dose gabapentin is superior to placebo in improving patient reported pain scores using the 0-10 numerical rating scale (NRS) from baseline to 4 weeks after the end of chemoradiation therapy.

EXPLORATORY OBJECTIVES:

I. To explore the duration of opioid use from the time of initiation to cessation by arm as well as describe the proportion of patients remaining on opioids at 3 months, 6 months, and 1 year by arm.

II. To explore the trajectory of patient reported symptom and quality of life outcomes using the Oral Mucositis Weekly Questionnaire (OMWQ) by arm.

III. To explore the trajectory of patient reported symptom and quality of life outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30) by arm.

IV. To explore the trajectory of patient reported symptom and quality of life outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck-43 (EORTC QLQ-H\&N43) by arm.

V. To evaluate the adverse event profiles of prophylactic high dose gabapentin versus placebo.

VI. To assess the tolerance of high dose gabapentin. VII. To explore the trajectory of patient health using patient body mass index (BMI) and creatinine, absolute neutrophil count (ANC) as routinely obtained by arm.

VIII. To describe the incidence of feeding tube requirement during and after chemoradiation therapy by arm.

IX. To describe the dose of prescribed opioids standardized using the Morphine Milligram Equivalent calculator by arm.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Starting by radiation treatment 8, patients receive placebo orally (PO) once daily (QD) on day 1, twice daily (BID) on day 2, then three times daily (TID) starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with placebo continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive placebo TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.

ARM II: Starting by radiation treatment 8, patients receive gabapentin PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with gabapentin continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive gabapentin TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 4 weeks, 3 months and 6 months after the last dose of chemoradiation therapy.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
  • Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic documentation of disease: Squamous cell carcinoma of the head and neck region.

    * Stage: I-IV

  • No prior treatment for head and neck cancer
  • Planned treatment with cisplatin-based chemoradiation therapy (weekly or once every 3 weeks [q 3 week])
  • Able to swallow capsules whole
  • No known to gabapentin or its ingredients
  • No patients on dialysis or with transplanted organs
  • No prior surgery or radiation for head and neck cancer and/or are being treated for recurrent head and neck cancer. Patients with a history of surgery and radioactive iodine for the treatment of thyroid cancer are eligible. Concurrent cancer therapy for other cancers is not allowed
  • No planned surgery or chemotherapy or immunotherapy following 7 weeks of standard chemoradiation treatment
  • No known
  • No nonprescribed use of any opioids (including heroin) within 6 months prior to registration
  • No prescribed medications for chronic and/or long-term pain and/or neuropathy, including patients under treatment of a pain specialist or substance abuse programs. Acute post- medications are allowed if the patient has discontinued them 3 days prior to study registration
  • No current treatment with mefloquine
  • Age ≥ 18 years
  • (ECOG) performance status ≤ 2
  • Creatinine ≤ 1.5 x (ULN)
  • Not pregnant and not nursing, because this study involves both radiation and chemotherapy. In addition, the genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of , a negative pregnancy test done \< 7 days prior to registration is required. Women must agree to using for the duration of receiving study drugs and for 6 months after completing chemoradiation
  • Not taking medications for a psychotic psychiatric illness
  • No existing diagnosis of sleep apnea
  • No acute narrow-angle glaucoma
  • No uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • No agent within 30 days prior to registration
  • No enrollment on other studies of systemic pain control agents
  • Language: In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish
  • Patients with impaired decision making are not eligible for study

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
228 participants (estimated)

Study arms

  • Placebo comparator
    Arm I (Placebo)

    Starting by radiation treatment 8, patients receive placebo PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with placebo continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive placebo TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.

    Drug: Placebo · Drug: Chemotheraphy · Radiation: Radiation Therapy · Drug: Analgesic Agent · Procedure: Biospecimen Collection · Other: Survey Administration

  • Experimental
    Arm II (Gabapentin)

    Starting by radiation treatment 8, patients receive gabapentin PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with gabapentin continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive gabapentin TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study.

    Drug: Gabapentin · Drug: Chemotheraphy · Radiation: Radiation Therapy · Drug: Analgesic Agent · Procedure: Biospecimen Collection · Other: Survey Administration

Interventions

  • Given PO

    Also known as: Gralise, Neurontin

  • DrugPlacebo

    Given PO

  • DrugChemotheraphy

    Receive standard of care chemotherapy

  • RadiationRadiation Therapy

    Undergo standard of care radiation

  • DrugAnalgesicsStudies of AnalgesicsAnalgesics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Receive standard of care pain medication

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Need to use opioids during chemoradiation therapy (CRT)

    Will be tested using a two-sample test of proportions. Will report the proportion of patients not using opioids within the 7 weeks of CRT in the two arms and the 95% confidence interval (CI) of the difference in the proportions.

    Time frame: Up to 7 weeks

Secondary outcomes

  1. Time to first opioid use

    Time to first opioid use, defined as the time from randomization to the first occurrence of opioid use during CRT, censoring patients alive and opioid free at CRT completion. Death or disease progression before first opioid use during CRT will be treated as competing events. Cumulative incidence functions will be used to estimate the percentage of patients who experience the competing events within the arms. Differences between the cumulative incidence functions between the arms will be tested for statistical significance using the procedure of Gray. The cumulative incidence percentage at the end of CRT by arm will be reported.

    Time frame: Up to 9 weeks

  2. Patient-reported pain scores

    Pain score responses of question #5 on the Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN) survey at each collected timepoint for each arm. This NRS item asks a respondent to rate their overall mouth and throat soreness during the past week from 0 (no soreness) to 10 (worst possible soreness). Will apply longitudinal modeling of the patient-reported pain scores through four weeks post CRT treatment. Will report each time-specific comparison between arms with a 95% CI.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

Other outcomes

  1. Need to use opioids during CRT by sex

    Will be assessed between arms and the corresponding 95% CIs will be provided by sex (male; female).

    Time frame: Up to 7 weeks

  2. Need to use opioids during CRT by race

    Will be assessed between arms and the corresponding 95% CIs will be provided by race (white; other).

    Time frame: Up to 7 weeks

  3. Need to use opioids during CRT by ethnicity

    Will be assessed between arms and the corresponding 95% CIs will be provided by ethnicity (Not Hispanic or Latino; Hispanic or Latino).

    Time frame: Up to 7 weeks

  4. Duration of opioid use

    Will report the number of patients and descriptively summarize the duration of opioid use from the time of initiation to cessation, or 4 weeks post-CRT (acute opioid use), whichever comes first. Descriptive statistics will include the mean, standard deviation, median, interquartile range, minimum, and maximum.

    Time frame: Though 4 weeks post CRT (up to 14 weeks)

  5. Global health

    Measured via OMWQ-HN. The first two items of the OMWQ-HN assess global health and quality of life and are rated on a seven-point scale, with one indicating very poor and seven indicating excellent. The focus will be on the interaction effect, which concerns comparisons of the patterns of changes in the mean patient-reported pain scores. In addition to plotting the model-based mean response profiles by arm, will report each time specific comparison between arms with a 95% CI.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

  6. Patient reported oral mucositis symptoms.

    Measured via OMWQ-HN. The third item of the OMWQ-HN assesses mouth and throat soreness and is rated on a five-point scale, with zero indicating no soreness and four indicating extreme soreness. The focus will be on the interaction effect, which concerns comparisons of the patterns of changes in the mean patient-reported pain scores. In addition to plotting the model-based mean response profiles by arm, will report each time specific comparison between arms with a 95% CI.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

  7. Mouth and throat soreness

    Measured via OMWQ-HN. The last three items of the OMWQ-HN assess the degree of mouth and throat pain and soreness using an 11-point scale, with zero indicating no pain or soreness and 10 indicating the worst pain or soreness imaginable or possible. The focus will be on the interaction effect, which concerns comparisons of the patterns of changes in the mean patient-reported pain scores. In addition to plotting the model-based mean response profiles by arm, will report each time specific comparison between arms with a 95% CI.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

  8. Impact of mouth and throat soreness on patient function

    Measured via OMWQ-HN. The fourth item of the OMWQ-HN, which is made up six different activities each rated on a five-point scale (0 = not limited and 4 = unable to do), assesses the impact of mouth and throat soreness on patient function; responses to the six different activities are summed (range: 0 to 24), with lower scores being better. The focus will be on the interaction effect, which concerns comparisons of the patterns of changes in the mean patient-reported pain scores. In addition to plotting the model-based mean response profiles by arm, will report each time specific comparison between arms with a 95% CI.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

  9. Incidence of symptoms or problems

    Measured on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck-43. The scales and singles arms range from 0-100, with higher scores indicating fewer symptoms or problems; a change of 10 units on the 0-100 response scale is regarded as considered clinically important. The focus will be on the interaction effect, which concerns comparisons of the patterns of changes in the mean patient-reported pain scores. In addition to plotting the model-based mean response profiles by arm, will report each time specific comparison between arms with a 95% CI.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

  10. Incidence of adverse events (AE)

    As scored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0). Will be summarized within arms by reporting the number and percentages of patients. Specifically, to evaluate the AE profiles within each arm, the maximum grade for each type of AE will be recorded for each patient and frequency tables will be reviewed to determine overall patterns; additionally, the proportion of somnolence, confusion, and gait disturbance using NCI CTCAE v 5.0 will be estimated within arms with the exact 90% CI.

    Time frame: Up to approximately 2 years

  11. Tolerance of gabapentin

    Defined as ≥ 80% adherence (yes; no) to gabapentin during CRT. The proportion of patients that complete CRT and tolerate gabapentin during CRT will be reported.

    Time frame: Up to the 9 weeks

  12. Body mass index

    Descriptive statistics will include the mean, standard deviation, median, interquartile range, minimum, and maximum.

    Time frame: Up to the 9 weeks

  13. Creatinine

    Descriptive statistics will include the mean, standard deviation, median, interquartile range, minimum, and maximum.

    Time frame: Up to the 9 weeks

  14. Absolute neutrophil count

    Descriptive statistics will include the mean, standard deviation, median, interquartile range, minimum, and maximum.

    Time frame: From baseline to the completion of CRT

  15. Dose of prescribed opioids

    The patient average dose of prescribed opioids will be standardized using the Morphine Milligram Equivalent calculator. Will summarize the within patient average dose of prescribed opioids according to arm using the mean, standard deviation, median, interquartile range, minimum, and maximum values.

    Time frame: Up to 7 weeks.

  16. Incidence of Feeding Tube

    Will report the frequency and percentage of patients within each arm who require a feeding tube during CRT.

    Time frame: Through 4 weeks post CRT (up to 14 weeks)

07

Study locations

191 of 216 sites recruiting

Showing the first 100 of 216 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2029, 50 months after the start.

Of 51 non-industry phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 67 and three quarters within 121. This study's planned 50 months is below that.

Counting every sponsor, half of 78 studies reached it within 76 months; a quarter within 38 and three quarters within 117.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 28, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Aug 15, 2029
CompletionEst.
Apr 15, 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 5 sites removed. 9 sites changed recruiting status (7 now recruiting, 2 now active, not recruiting)
Show 9 sites
  • Carle at The Riverfront · Danville, United StatesSuspended→Recruiting
  • Carle Physician Group-Effingham · Effingham, United StatesSuspended→Recruiting
  • Carle Physician Group-Mattoon/Charleston · Mattoon, United StatesSuspended→Recruiting
  • Carle BroMenn Medical Center · Normal, United StatesSuspended→Recruiting
  • Carle Cancer Institute Normal · Normal, United StatesSuspended→Recruiting
  • Carle Cancer Center · Urbana, United StatesSuspended→Recruiting
  • Methodist Jennie Edmundson Hospital · Council Bluffs, United StatesSuspended→Active, not recruiting
  • Nebraska Methodist Hospital · Omaha, United StatesRecruiting→Active, not recruiting
  • Trinity Medical Center · Moline, United StatesSuspended→Recruiting
Show 21 added (21 United States)
  • Mayo Clinic Hospital in Arizona · Phoenix, United States
  • University of Arkansas for Medical Sciences · Little Rock, United States
  • UCHealth Memorial Hospital Central · Colorado Springs, United States
  • Memorial Hospital North · Colorado Springs, United States
  • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United States
  • Kaiser Permanente-Lone Tree · Lone Tree, United States
  • Mayo Clinic Health System in Albert Lea · Albert Lea, United States
  • Mayo Clinic Health Systems-Mankato · Mankato, United States
  • Mayo Clinic in Rochester · Rochester, United States
  • Ohio State University Comprehensive Cancer Center · Columbus, United States
  • UPMC Hillman Cancer Center · Pittsburgh, United States
  • Aspirus Cancer Care-Antigo-Volm Cancer Center · Antigo, United States
  • Mayo Clinic Health System-Eau Claire Clinic · Eau Claire, United States
  • Mayo Clinic Health System-Franciscan Healthcare · La Crosse, United States
  • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center · Rhinelander, United States
  • Aspirus Cancer Care-Wausau · Wausau, United States
  • Memorial Hospital of Laramie County · Cheyenne, United States
  • SSM Health Good Samaritan · Mount Vernon, United States
  • Mercy Cancer Center-West Lakes · Clive, United States
  • Mercy Medical Center - Des Moines · Des Moines, United States
  • Peninsula Cancer Institute-Newport News · Newport News, United States
Show 5 removed
  • Saint Anthony Hospital · Lakewood, United States
  • University of Pittsburgh Cancer Institute (UPCI) · Pittsburgh, United States
  • Langlade Hospital and Cancer Center · Antigo, United States
  • Aspirus Cancer Care - James Beck Cancer Center · Rhinelander, United States
  • Aspirus Regional Cancer Center · Wausau, United States
across 2 updates, Oct 2, 2026 – Nov 4, 2026
Site contacts
Changed at 14 sites. See the sites
Show 14 sites
  • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
  • Carle at The Riverfront · Danville, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
  • Carle Physician Group-Effingham · Effingham, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
  • Carle Physician Group-Mattoon/Charleston · Mattoon, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
  • Carle BroMenn Medical Center · Normal, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
  • Carle Cancer Institute Normal · Normal, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
  • Carle Cancer Center · Urbana, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
  • Nebraska Methodist Hospital · Omaha, United StatesContact removed •••5144Contact removed (no phone or email listed)
  • Aultman Health Foundation · Canton, United StatesContact person changed (no phone or email listed)
  • Geisinger Medical Center · Danville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Cancer Center Dickson City · Dickson City, United StatesContact h•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Medical Oncology-Lewisburg · Lewisburg, United StatesContact •••8555→•••9200Contact H•••@geisinger.edu→c•••@geisinger.edu
  • Geisinger Cancer Services-Pottsville · Pottsville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
  • Trinity Medical Center · Moline, United StatesContact added •••2000Contact added (no phone or email listed)
across 2 updates, Oct 2, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    4 sites added. 2 sites changed recruiting status (1 now suspended, 1 now recruiting)
    Show 2 sites
    • Rush-Copley Medical Center · Aurora, United StatesRecruiting→Suspended
    • Trinity Medical Center · Moline, United StatesSuspended→Recruiting
    Show 4 added (4 United States)
    • SSM Health Good Samaritan · Mount Vernon, United States
    • Mercy Cancer Center-West Lakes · Clive, United States
    • Mercy Medical Center - Des Moines · Des Moines, United States
    • Peninsula Cancer Institute-Newport News · Newport News, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Rush-Copley Medical Center · Aurora, United StatesContact removed R•••@rush.edu · •••6212Contact removed (no phone or email listed)
    • Trinity Medical Center · Moline, United StatesContact added •••2000Contact added (no phone or email listed)
    + 1 other change: verification date
  2. Oct 2, 2026
    17 sites added, 5 sites removed. 9 sites changed recruiting status (7 now recruiting, 2 now active, not recruiting)
    Show 9 sites
    • Rush-Copley Medical Center · Aurora, United StatesSuspended→Recruiting
    • Carle at The Riverfront · Danville, United StatesSuspended→Recruiting
    • Carle Physician Group-Effingham · Effingham, United StatesSuspended→Recruiting
    • Carle Physician Group-Mattoon/Charleston · Mattoon, United StatesSuspended→Recruiting
    • Carle BroMenn Medical Center · Normal, United StatesSuspended→Recruiting
    • Carle Cancer Institute Normal · Normal, United StatesSuspended→Recruiting
    • Carle Cancer Center · Urbana, United StatesSuspended→Recruiting
    • Methodist Jennie Edmundson Hospital · Council Bluffs, United StatesSuspended→Active, not recruiting
    • Nebraska Methodist Hospital · Omaha, United StatesRecruiting→Active, not recruiting
    Show 17 added (17 United States)
    • Mayo Clinic Hospital in Arizona · Phoenix, United States
    • University of Arkansas for Medical Sciences · Little Rock, United States
    • UCHealth Memorial Hospital Central · Colorado Springs, United States
    • Memorial Hospital North · Colorado Springs, United States
    • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United States
    • Kaiser Permanente-Lone Tree · Lone Tree, United States
    • Mayo Clinic Health System in Albert Lea · Albert Lea, United States
    • Mayo Clinic Health Systems-Mankato · Mankato, United States
    • Mayo Clinic in Rochester · Rochester, United States
    • Ohio State University Comprehensive Cancer Center · Columbus, United States
    • UPMC Hillman Cancer Center · Pittsburgh, United States
    • Aspirus Cancer Care-Antigo-Volm Cancer Center · Antigo, United States
    • Mayo Clinic Health System-Eau Claire Clinic · Eau Claire, United States
    • Mayo Clinic Health System-Franciscan Healthcare · La Crosse, United States
    • Aspirus Cancer Care-Rhinelander-James Beck Cancer Center · Rhinelander, United States
    • Aspirus Cancer Care-Wausau · Wausau, United States
    • Memorial Hospital of Laramie County · Cheyenne, United States
    Show 5 removed
    • Saint Anthony Hospital · Lakewood, United States
    • University of Pittsburgh Cancer Institute (UPCI) · Pittsburgh, United States
    • Langlade Hospital and Cancer Center · Antigo, United States
    • Aspirus Cancer Care - James Beck Cancer Center · Rhinelander, United States
    • Aspirus Regional Cancer Center · Wausau, United States
    Site contacts Changed at 13 sites. See the sites
    Show 13 sites
    • Rush-Copley Medical Center · Aurora, United StatesContact added R•••@rush.edu · •••6212Contact added (no phone or email listed)
    • Carle at The Riverfront · Danville, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
    • Carle Physician Group-Effingham · Effingham, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
    • Carle Physician Group-Mattoon/Charleston · Mattoon, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
    • Carle BroMenn Medical Center · Normal, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
    • Carle Cancer Institute Normal · Normal, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
    • Carle Cancer Center · Urbana, United StatesContact added R•••@carle.com · •••5532Contact added (no phone or email listed)
    • Nebraska Methodist Hospital · Omaha, United StatesContact removed •••5144Contact removed (no phone or email listed)
    • Aultman Health Foundation · Canton, United StatesContact person changed (no phone or email listed)
    • Geisinger Medical Center · Danville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Cancer Center Dickson City · Dickson City, United StatesContact h•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Medical Oncology-Lewisburg · Lewisburg, United StatesContact •••8555→•••9200Contact H•••@geisinger.edu→c•••@geisinger.edu
    • Geisinger Cancer Services-Pottsville · Pottsville, United StatesContact H•••@geisinger.edu→c•••@geisinger.edu
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06992427
Responsible party
Sponsor
First posted
May 28, 2025
Start date
Jun 5, 2025
Primary completion
Aug 15, 2029 (estimated)
Completion
Apr 15, 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Nancy Garcia
Contact
cancercontrolprotocols@alliancenctn.org
773-702-9171

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion